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ABSTRACT
Allergen-specifi c immunotherapy (ASIT) is a method of specifi c treatment of atopic dermatitis (AD) 
which has been used for years in human and veterinary medicine. It is empirically known to be effective in 
dogs with AD, however, its true effectiveness still seems controversial due to insuffi cient evidence derived 
from controlled studies. The purpose of this study was to compare the results of an 8-month ASIT with 2-month 
symptomatic methylprednisolone treatment in dogs with AD. The third version of Canine Atopic Dermatitis 
Extent and Severity Index (CADESI-03) was used for the fi rst time for objective evaluation of ASIT effi cacy 
in dogs. 11 atopic dogs, older than 6 months, of various breeds and both sexes, were included in the study. 
Each dog was initially treated with methylprednisolone over a period of 2 months. After a washout period of 
1 month, conventional ASIT with subcutaneous allergen injections was initiated and continued for the next 8 
months. CADESI-03 scores were evaluated at regular monthly control visits. In both groups, ≥50% reduction of 
CADESI-03 score from baseline was recorded in 4/11 dogs (36,4%). A signifi cant effect of ASIT was recorded 
after 6 months of therapy (P = 0.032). Thus, at least a period of 6 months is recommended before assessing 
treatment effi cacy of ASIT. Methylprednisolone proved to be more effi cient in controlling pruritus than ASIT. 
No remarkable changes in blood biochemical parameters were observed in either group. The results of our 
study suggest that the effect of 8-month ASIT in dogs with AD is comparable to that of 2-month therapy with 
methylprednisolone. The obvious safety of long-term ASIT additionally supports the more frequent use of this 
specifi c therapy in the treatment of canine AD.
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Introduction
Atopic dermatitis (AD) is a common allergic skin disease of dogs with a high 
incidence in Europe and other industrialised countries (HILLIER and GRIFFIN, 2001). It 
has been consensually defi ned as a genetically-predisposed infl ammatory and pruritic 
allergic skin disease with characteristic clinical features, most commonly associated with 
a combination of IgE-mediated immediate and late phase reactions to environmental 
allergens (OLIVRY et al., 2001). 
Allergen-specifi c immunotherapy (ASIT) is currently known as the only specifi c 
(causal) treatment of canine AD. ASIT is the practice of administering gradually increasing 
quantities of an allergen extract to an allergic subject to ameliorate the symptoms 
associated with subsequent exposure to the causative allergen (BOUSQUET, 1998). The 
terms desensitization and hyposensitization, which have also been used previously to 
describe this form of therapy, refer to the primary goal of ASIT, i.e. a reduction or loss of 
sensitivity in a patient (GRIFFIN and HILLIER, 2001). Allergens are given by subcutaneous 
injection in increasing doses up to the maintenance dose. No standardized ASIT regimens 
exist in veterinary medicine. Treatment regimens vary in terms of the type of allergens 
used, according to the amount of allergens injected and the frequency of injections 
(SÆVIK et al., 2002). Results of intradermal or serologic allergy tests are used to identify 
and select allergens for inclusion in ASIT medicament. Treatment recommendations 
are usually provided by a specialized laboratory that manufactures immunotherapeutic 
vaccines, making ASIT of atopic dogs readily available for general practitioners.
ASIT has been used for years to treat humans with atopic diseases as well as dogs 
with atopic dermatitis, but its effectiveness still seems quite controversial. The majority 
of multiple open studies and a large body of clinical observations suggest that ASIT is 
effective in controlling the clinical signs of dogs in approx. 70% of patients with AD. 
Approximately 25% of dogs can have their skin disease controlled with immunotherapy 
alone, whereas about 40% show a benefi cial response together with other forms of treatment 
(HILL, 2007). There is cumulative clinical evidence of the effect of immunotherapy in both 
humans and dogs. Recent research in veterinary science provide us with supportive data 
on immunologic mechanisms: it seems that lower levels of IgE and elevated production 
of specifi c IgG1 and IgG4 follows ASIT as a consequence of higher levels of T-regulatory 
cells that produce large amounts of IL-10 (KEPPEL et al., 2008). In human medicine there 
have been several changes in immune reactions to allergens already documented and they 
include a decreased number of infl ammatory cells (particularly mast cells, basophils and 
eosinophils), decline of IgE and increase of IgG1 and IgG4 levels, increased production 
of IFN-γ and reduced production of IL-4 in T-cell cultures. ASIT is considered safe for 
long-term use as it rarely causes adverse systemic reactions. The most frequent side 
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effects are localized swelling, erythema, pain or pruritus at the injection site (GRIFFIN 
and HILLIER, 2001).
The majority of previous fi ndings regarding the effectiveness of ASIT in atopic dogs 
were mostly empirical, although this method of treatment of canine AD has been used 
for more than 50 years. Up to now, studies evaluating ASIT effi cacy in dogs have been 
based either upon a dog owner’s subjective perception of health improvement (inquiries), 
measurement of pruritus scores, a global measure of the veterinarian’s perception of 
the patient’s improvement at the end of the study and the patient’s need for additional 
(supportive) therapy or, fi nally, upon the two CADESI scoring systems. Combined and 
modifi ed scoring systems have rarely been used. 
The third version of Canine Atopic Dermatitis Extent and Severity Index (CADESI-
03) is the latest scale for scoring skin lesions in dogs with AD, designed by a committee 
of the International Task Force on Canine Atopic Dermatitis (ITFCAD) and it is currently 
recommended as the only properly validated and objective assessment tool for use in 
clinical trials involving dogs with AD (OLIVRY et al., 2007). To our knowledge it has not 
yet been used in a clinical trial evaluating the effectiveness of ASIT. 
Methylprednisolone was proven to be highly effective for the treatment of allergic 
dogs, when administered at 0.4-0.8 mg/kg once daily for 7 days, then every other day 
(GUAGUÈRE, 1996). It may serve as a reliable control drug because of its quick and strong 
effect on pruritus and other allergy symptoms.
The objectives of this study were to evaluate the effectiveness and safety of 8-month 
ASIT compared to methylprednisolone treatment in atopic dogs, using CADESI-03 
scoring system.
Materials and methods
Inclusion criteria. The study included 11 dogs, older than 6 months (from 12 to 81 
months, median 28 months), of various breeds (2 Golden Retrievers, 1 each Labrador 
Retriever, Fox Terrier, American Staffordshire Terrier, St. Bernard, medium-sized 
Poodle, Czech Terrier, West Highland White Terrier and 2 mixed-breed dogs), both sexes 
(6 females and 5 males) and different weights (from 6 to 47 kg, median 25 kg). All dogs 
had been brought to the Clinic for Small Animal Medicine and Surgery of the Veterinary 
Faculty of Ljubljana (CSAMS) due to skin problems and were diagnosed with atopic 
dermatitis.
Prior to the start of the study, microscopic examination of skin scrabs, skin swabs and 
serologic allergy testing were carried out to exclude parasitic skin diseases, secondary 
infections and Flea allergy dermatitis. During the study, the dogs were treated with 
long-acting anti-fl ea products such as fi pronil (Frontline Spot-on; Merial, France) or 
selamectine (Stronghold; Pfi zer Luxembourg SARL, Luxemburg). To exclude the 
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possible infl uence of a concurrent food allergy, all dogs were fed an elimination diet 
during the study period and were not rechallenged until the end. Amongst the diets an 
individually adjusted home-made diet and Eucanuba FP Dermatosis were preferred. 
When secondary pyoderma appeared during the study it was controlled by use of oral 
enrofl oxacine (Enroxil; Krka, Slovenija) in a dose of 5 mg/kg SID and/or chlorhexidine 
shampoo twice weekly (Chlorexyderm forte shampoo, ICF, Italy). Malassezia dermatitis 
was controlled by use of enilconazole dips twice-weekly (Zoniton; Krka, Slovenija). 
Otitis externa was controlled by Epi-Otic (Virbac Animal Health, France). For each dog, 
serologic allergy tests (ELISA) for 32 environmental allergens were performed by the 
Alergovet S.L. laboratory (Madrid, Spain). The clinical diagnosis of atopic dermatitis was 
based upon the fulfi llment of at least 3 major and 3 minor diagnostic criteria proposed 
by Willemse (WILLEMSE, 1986), amongst them pruritus, chronic dermatitis, elevated 
allergen-specifi c IgE and onset of signs before 3 years of age were criteria present in all 
the dogs included.
Non-inclusion and exclusion criteria. Dogs that fulfi lled any of the following criteria 
could not be enrolled or were excluded from the clinical trial during the study period:
Dogs with inadequately documented history of the disease, previous therapies and 
their outcome;
Dogs with health conditions that would hinder the evaluation of the disease (like 
cushing, mastocytoma etc.);
Dogs with serious liver or kidney dysfunction;
Planned or accidental pregnancy;
Dogs in which the elimination diet was not strictly followed;
Dogs treated with the following drugs:
glucocorticoids: less than 4 weeks prior to inclusion,
antihistamines: less than 14 days prior to inclusion,
cyclosporines: less than 30 days prior to inclusion,
essential fatty acid supplements: less than 14 days prior to inclusion,
vitamin E supplements: less than 14 days prior to inclusion,
antipruritic agents such as serotonin reuptake inhibitors (SRI) and selective 
serotonin reuptake inhibitor (SSRI): less than 14 days prior to inclusion,
previus allergen-specifi c immunotherapy. 
Study design. After being included in the study, all 11 dogs were treated with 
methylprednisolone (Medrol; Pfi zer Luxembourg SARL, Luxemburg in the dose of 0.5 
mg/kg PO SID for 5 days, followed by the same dose QOD) over a period of 2 months 
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(group M). After that, a washout period of 1 month was essential to achieve complete 
elimination of methylprednisolone infl uence. A conventional ASIT with subcutaneous 
allergen injections was then initiated and continued for the next 8 months according to 
the recommended regimen (Table 1) provided by the Alergovet S.L. laboratory (group I). 
Allervet™-Ca immunotherapeutic vaccines (Stallergenes S.A. laboratory, Antony Cedex, 
France) were manufactured according to the results of serologic allergy tests for each dog 
individually. 
CADESI-03 was derived from the previous two CADESI scoring systems and 
presented in 2007. It was generated by combining an evaluation of the degree of severity 
(none (0), mild (1), moderate (2-3) and severe (4-5)) for each of the four cardinal signs of 
canine AD (erythema, excoriation, lichenifi cation and self-induced alopecia) on each of 
62 different body areas. The maximum score of CADESI-03 is therefore 1240. CADESI-
03 scores were evaluated at regular monthly control visits. To ensure the highest level of 
reliability and objectivity, a representative photo-table for CADESI-03 scoring system 
was created prior to the study using photographs of dogs in different clinical stages of 
atopic dermatitis, examined at CSAMS in the past. A reduction of 50% or higher of 
CADESI-03 was considered as a major outcome measure of treatment effi cacy.
Dermal pruritus was also assessed. The assessment was based upon observations 
made by the dog owners. Pruritus was evaluated using the visual analog scale, which 
enabled the owners to record their evaluation by scoring on a 0 to 100 scale. Their 
evaluation was based on their assessment of intensity, frequency and duration of pruritus. 
They were instructed to pay attention to the various actions of licking, biting, scratching 
and rubbing against objects.
The safety of each therapy was assessed monthly by blood tests of liver enzymes 
(alkaline phosphatase - AP, alanine transferase - ALT) and urea and creatinine as indicators 
of renal function. Biochemical blood parameters were determined by the Technicon RA-
XT biochemical analyzer (Bayer Technicon, Germany). 
Table 1. Allergen-specifi c immunotherapy regimen for the vaccine Allervet™-Ca (Alergovet S.L., 
Spain, in collaboration with Stallergenes S.A., France)
Week 1 2 3 4 5 6 7 8 9 10 11 13 16 20 24→
Concentration 0,1 IE/mL 1 IE/mL 10 IE/mL
Dose (mL) 0.2 0.4 0.8 1.0 0.2 0.4 0.8 1.0 0.2 0.4 0.8 1.0 1.0 1.0 1.0→
Statistical evaluation of the results. A small number of tested animals provided a 
small number of results in one group which were not normally distributed. However, the 
assumptions of the parametric tests were not satisfi ed. Therefore we used non parametric 
tests which do not make any distributional assumptions about the data and are appropriate 
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for a small number of observations. The analyses in non-parametric tests are performed 
on the ranks of the observations instead of the original observations.
Within each group, CADESI values recorded at each time point were compared using 
a nonparametric repeated - measures analysis of variances (Friedman repeated measures 
analysis of variances on ranks) and Dunn’s multiple comparison post-test. 
To evaluate whether CADESI scores for each group separately had changed between 
the start and the selected time point of the study, Wilcoxon signed rank tests were 
performed for paired samples.
The reduction in CADESI between the start and end point of group M was compared 
with the reduction of CADESI in group I for each time interval, from the starting point 
using the Wilcoxon signed rank test.
The Pearson correlation coeffi cient was used to determine the relationship between 
the estimated pruritus and CADESI scores, as well as to test the correlation in CADESI 
scores between both groups at the beginning of the treatment.
The proportion of dogs in each group with a measure of selected biochemical 
parameters above or below the physiological value was summarized using frequency 
tables and the groups were compared using Fisher’s exact test.
For all statistical analyses, P<0.05 was taken to indicate signifi cance.
Statistical analysis was performed using SigmaStat 3.5 (SYSTAT Software Inc.)
Results
Results of serologic allergy testing performed by Alergovet laboratory (Madrid, Spain) 
showed that 7/11 dogs (63.6%) had been sensitized against the group of storage mites and 
the house dust mite Dermatophagoides farinae. These were therefore recognized as the 
most frequent allergens responsible for the development of atopic disease in our dogs. 
In the studied dogs, three dogs (27.3%) were sensitized at the same time against plant 
allergens (pollens of grasses, trees and weeds). Four dogs (36.4%) were sensitised against 
plant allergens alone. Three of them lived exclusively in an urban environment (numbers 
8, 10 and 11) and the fourth (number 7) lived most of the time in an urban environment. 
The highest number of allergens identifi ed in one dog was 10, and the lowest 2. 
Concurrent events observed during methylprednisolone therapy were polyuria/
polydypsia (27.3%), otitis externa (18.2%), Malassezia dermatitis (18.2%), respiratory 
symptoms (18.2%), bacterial pyoderma (9.1%) and gastrointestinal problems (9.1%).
The most common concurrent event noticed during ASIT was local erythema and 
itching at the site of the allergen injection, noticed in 72.7% of dogs. Both signs typically 
lasted for a short period of time and usually disappeared one day after injection. These 
signs no longer appeared in any of the dogs when the maintenance dose of ASIT vaccine 
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had been reached. Other concurrent events noticed during ASIT were conjunctivitis 
(45.5%), otitis externa (36.4%), gastrointestinal problems (36.4%), bacterial pyoderma 
(27.3%), generalized pruritus with erythema 18.2%), respiratory symptoms (9.1%) and 
other (9.1%). Some of them were mild and therefore only observed (like conjunctivitis, 
gastrointestinal problems and respiratory symptoms) while others were treated (see 
inclusion criteria). Eight dogs undergoing ASIT (72.7%) therefore required additional 
topical therapy, such as ear drops (36.4%), antibiotic creams/ointments or antipruritic 
shampoos (27.3%). Two dogs required systemic antipruritic therapy (glucocorticoids and/
or antihistamines) and were therefore excluded from the study.
Fig. 1 shows that a ≥50% reduction of the total CADESI-03 score from the baseline 
was achieved in four dogs (36.4%) treated with methylprednisolone. In two patients, such 
a reduction was already achieved after the fi rst month of methylprednisolone therapy, 
whereas in the other two, two months of therapy were needed for such a result to be 
achieved. Six dogs experienced a <50% reduction of total CADESI-03 scores after two 
months of therapy, whereas the clinical state of one dog even deteriorated after two months 
of therapy. The CADESI-03 scores became signifi cantly different from the baseline scores 
after 2 months of methylprednisolone therapy (P = 0.015).
Fig. 2 shows that a ≥50% reduction of total CADESI-03 score from the baseline was 
achieved in four dogs (36.4%) treated with ASIT. Such a reduction was recorded after 
3 months of ASIT in two dogs and after 6 months of ASIT in another two. Patients 2 
and 5 required systemic antipruritic therapy (glucocorticoids and/or antihistamines) and 
were excluded from the study. The scores became signifi cantly different from the baseline 














Fig. 1. Changes in CADESI-03 scores (%) during the period of methylprednisolone therapy 
(group M)
Patient number
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Comparison of total CADESI-03 scores after the 1-month washout period (prior 
to ASIT) with the baseline (prior to methylprednisolone therapy) showed a signifi cant 
positive correlation (r = 0.75, P<0.01). Additional statistical analysis did not reveal 
signifi cant differences between total CADESI-03 scores prior to methylprednisolone 
therapy and those prior to ASIT (P = 0.649, data not shown).
From Fig. 1 and Fig. 2 we can observe that in as many as fi ve studied dogs (45.5%), 
a larger reduction in total CADESI-03 score was recorded after 8 months of ASIT than 
after 2 months of methylprednisolone therapy.
Fig. 3 compares the mean changes of CADESI-03 between both groups in relation to 
months of therapy. The fastest effect of methylprednisolone was recorded after the fi rst 
month of therapy, whereas ASIT caused the most rapid improvement after the second 














Fig. 2. Changes in CADESI-03 scores (%) during the period of ASIT (group I)
Patient number
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The effect of ASIT was comparable to that of 2-month methylprednisolone therapy 
after 3 months of therapy, as there was no signifi cant difference between improvements in 
total CADESI-03 scores caused by both therapies at that time (P = 0.492).
Fig. 4 compares mean changes in pruritus score between both groups in relation 
to months passed. The quick and strong favorable effect of methylprednisolone on 
pruritus was evident, whereas the mean reduction in estimated pruritus score stagnated at 
approximately -20% during ASIT.
Comparison of CADESI-03 scores with estimated pruritus scores revealed a 
signifi cant positively correlation (r = 0.564, P<0.01) in the same therapy group.
No remarkable changes in blood biochemical parameters (urea, creatinine, AP, ALT) 
were seen in either group (data not shown). The Fisher exact test revealed no statistically 
signifi cant differences between urea, creatinine, AP and ALT (P = 0.745, 1,000, 1,000 and 
1,000, respectively) in either of the groups compared to the baseline levels.
Discussion
The study included 11 atopic dogs. The nature of the study demanded regular and 
relatively long monitoring of patients treated with ASIT. For this purpose, the design of 
the study was rationalized and was based on a single group of dogs which served as a 
control group (group M, treated with methylprednisolone for 2 months) at the beginning 
of the research, and then, following a 1-month washout period, also as a test group (group 
I, treated with ASIT for 8 months). The main advantage of such a single research group 
was the exclusion of individual differences between two different samples of animals 
(upon which the majority of known similar studies has been based) and the elimination 
of the possible infl uence these differences might have on the objectivity of comparative 
analysis of groups (NOURBAKHSH and OTTENBACHER, 1994). On the other hand, non-
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simultaneous comparison of two different therapies in two different periods could be 
characterized as the main negative aspect of this study design. The probable reason for 
the worsening of CADESI scores during methylprednisolone treatment in three dogs 
(numbers 5, 6 and 9, see Fig. 1) could be contamination of dry foods with storage mites. 
The same may be true for exacerbation during ASIT in the dogs numbered 4, 6, 7 and 
9 (see Fig. 2). Since the effect of immunotherapy in storage mite hypersensitive dogs 
remains unclear they should be fed exclusively homemade elimination diets.
Serologic allergy tests were performed in order to select allergens for production 
of immunotherapeutic vaccines. When compared to individual dog histories, the results 
showed that plant allergen sensitizations were more frequent in dogs that lived in an 
urban environment. This phenomenon has already been described in human allergology 
(D’AMATO, 2002) and may refl ect a response otherwise described in fl ea allergy dermatitis 
(FAD) in dogs. It has been shown that FAD develops in dogs that are only intermittently 
exposed to fl eas (SCOTT et al., 2001). Something similar may be true for plant allergens. 
The washout period of 1 month was essential to achieve complete elimination of 
the infl uence of methylprednisolone. The duration of washout period was determined on 
the basis of recent studies that recommend a washout period of at least three weeks for 
peroral treatment with glucocorticoids (BEALE, 2006; OLIVRY et al., 2002). Total CADESI-
03 scores did not differ prior to both therapies (P = 0.649), therefore we can conclude that 
the chosen washout period was long enough for groups M and I to be independent. 
The percentage of study subjects achieving reduction of ≥50% of the CADESI 
score (partial remission) has been determined as one of the clinically relevant outcome 
measures of treatment effi cacy in dogs with AD (OLIVRY et al., 2007). Many times higher 
percentages (59-64%) of ASIT treated dogs have been reported to achieve ≥50% reduction 
of lesion scores (WILLEMSE et al., 1984; NUTTALL et al., 1998; SCHNABL et al., 2006). 
Unfortunately data gained by the use of different scoring systems are hardly comparable. 
Therefore we decided to use methylprednisolone treatment as the standard of care. 
This drug is generally known as being highly effective and exhibits a short elimination 
half-life that allows alternate day prescription modalities (GUAGUÈRE et al., 1996). The 
two-month methylprednisolone treatment in our study showed similar effi cacy to ASIT, 
lowering the CADESI-03 score by ≥50% in the same number of dogs (4/11 = 36,4%). The 
same proportion of ≥50% reductions of CADESI-03 with ASIT was reported by Mueller 
in 2005 (MUELLER et al., 2005). Since the major improvement of clinical signs and the 
signifi cant effect of ASIT were recorded after 6 months of therapy, this period can be 
recommended as the shortest treatment period after which ASIT effi cacy may be critically 
assessed. For comparison, Willemse proposed a critical period of 9 months to objectively 
evaluate ASIT effi cacy (WILLEMSE et al., 1984).
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The estimated pruritus score is a parameter which indicates treatment effi cacy much 
more rapidly than any lesion score. It has been shown that 6-week treatment of canine AD 
is too short to achieve complete remission of certain skin lesions (e.g. lichenifi cation) that 
require a longer period to be cured (OLIVRY et al., 2002). On the other hand, the pruritus 
score is more subjective than the CADESI lesion score and we need to evaluate it more 
rigorously. Some authors propose that ≥70% of study subjects need to achieve ≥50% 
reduction of pruritus as one of the standard outcome measures of treatment effi cacy for 
canine AD (BEALE, 2006). In the ASIT group, ≥50% reduction of pruritus was recorded 
in 55.6% (data not shown) of dogs, but not in all periods of treatment, as the treatment 
with ASIT was much longer than that with methylpednisolone and the dogs were more 
susceptible to seasonal and environmental changes in allergen concentration. A moderate 
response of pruritus to ASIT was expected and is comparable with other recent studies 
(COLOMBO et al., 2005). Since treatment with methylprednisolone is considered to be one 
of the most effi cient antipruritic therapies, high percentages of ≥50% reduction of pruritus 
were expected. After 2 months methylprednisolone therapy as many as 90.9% of dogs in 
our study experienced ≥50% reduction of pruritus (data not shown).
A comparable degree of correlation between pruritus and CADESI-03 scores was 
reported by the authors who validated the CADESI-03 system (OLIVRY et al., 2007). 
According to these results we can conclude that the lesion score in our study effi ciently 
followed the pruritus score. 
None of the previous studies described any signifi cant changes in blood biochemical 
parameters in patients undergoing ASIT and this was also confi rmed by the results of the 
present study. On the other hand, a 2-month and alternate-day treatment with low doses of 
methylprednisolone was short and safe enough for the patients not to exhibit the changes 
in blood biochemical parameters associated with long-term glucocorticoid therapy. We 
can therefore conclude that 8-month ASIT is as safe as 2-month methylprednisolone 
treatment. 
Conclusion
In conclusion, the results of our study suggest that the effect of 8-months ASIT 
in dogs with AD is comparable to that of 2-months therapy with methylprednisolone. 
Methylprednisolone is much more effective in controlling pruritus than ASIT, however 
the effects of ASIT and methylprednisolone in controlling skin lesions associated with 
CAD are totally comparable. The obvious safety of long-term ASIT additionally supports 
the more frequent use of this specifi c therapy in the future treatment of canine AD.
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SAŽETAK
Alergen specifi čna imunoterapija (ASIT) metoda je specifi čnoga liječenja atopijskog dermatititsa (AD) 
koja se godinama primjenjuje u humanoj i veterinarskoj medicini. Iskustveno je poznato da je učinkovita u pasa 
s AD, ali je njezina učinkovitost još uvijek prijeporna, jer nema dovoljno dokaza proizašlih iz kontroliranih 
istraživanja. Svrha ovoga istraživanja bila je usporediti rezultate 8-mjesečne ASIT s rezultatima dvomjesečnoga 
simptomatskoga liječenja AD pasa metilprednizolonom. Treća verzija određivanja stupnja i indeksa jačine 
atopijskoga dermatitisa u psa (engl. Canine Atopic Dermatitis Extent and Severity Index (CADESI-03)) prviput 
je bila rabljena za objektivnu prosudbu učinkovitosti ASIT u pasa. Jedanaest atopičnih pasa, starijih od šest 
mjeseci, različitih pasmina i različita spola bilo je uključeno u ovo istraživanje. Svaki je pas početno bio liječen 
prednizolonom tijekom dva mjeseca. Nakon jednomjesečne stanke, započeta je uobičajena ASIT sa supkutanom 
primjenom alergena u trajanju od sljedećih osam mjeseci. CADESI-03 bodovanje bilo je vrednovano prilikom 
redovitih mjesečnih kontrolnih pregleda. U obje skupine ustanovljeno je smanjenje CADESI-03 bodova ≥50% 
od bazičnoga u 4 od 11 pasa (36,4%). Značajni učinak ASIT-a bio je ustanovljen nakon šest mjeseci liječenja 
(P = 0,032). Stoga se procjena učinkovitosti ASIT-a može dati tek nakon liječenja od najmanje šest mjeseci. 
Metilprednizolon je bio učinkovitiji za suzbijanje svrbeža od ASIT-a. Nije bila ustanovljena značajna razlika 
u biokemijskim pokazateljima krvi među promatranim skupinama. Rezultati ovoga istraživanja pokazuju da 
je učinak 8-mjesečne alergen specifi čne imunoterapije u pasa s atopijskim dermatitisom jednak onome kod 
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dvomjesečnoga liječenja prednizolonom. Očita sigurnost dugotrajne ASIT dodatna je potpora sve češćoj 
upotrebi toga specifi čnoga liječenja atopijskoga dermatitisa pasa. 
Ključne riječi: atopijski psi, atopijski dermatitis, alergen specifi čna imunoterapija, hiposenzibilizacija, 
CADESI-03________________________________________________________________________________________
